XCUR (Exicure) FFO


XCUR Exicure Inc XCUR
30 GF Score
Price $2.40
GF Value $0.54
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exicure FFO?

FFO (Funds from operations) only applies to REITs.

XCUR
30GF Score
Exicure Inc XCUR
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exicure (XCUR) Overvalued in 2026?

Based on GuruFocus' analysis, Exicure stock appears to be overvalued. The current stock price of $2.40 is trading 344.4% above its estimated GF Value™ of $0.54. GuruFocus considers Exicure to be Significantly Overvalued.

Key valuation signals for XCUR:

  • FFO:
  • GF Value™: $0.54 vs. price of $2.40 (344.4% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the XCUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exicure Business Description

Other Exchanges 2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
30GF Score

Get the complete analysis for XCUR

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price
$0.54
GF Value